PTO/SB/08 (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE cond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/PTO			Complete If Known		
000				Application Number	Not Yet Assigned	
11	IFORMATI	ON DISC	LOSURE	Filing Date	Herewith	
STATEMENT BY APPLICANT				First Named Inventor	Reiner L. Gentz	
Ŭ	,,,,,,			Art Unit	N/A	
	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	1	of	8	Attorney Docket Number	PF402C1D1	

			U.S. PA	ATENT DOCUMENTS	
xaminer nitials*	Cite No.1	Document Number Number-Kind Code ² (il known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear
¥Z	AA	5,194,596	03/16/1993	Tischer et al.	
	AB	5,350,836	09/27/1994	Kopchick et al.	
	AC	5,580,856	12/03/1996	Prestrelski et al.	<u> </u>
	AD	5,677,278	10/14/1997	Gospodarowicz et al.	
	AE	5,703,047	12/30/1997	Wilson	
	AF	5,731,170	03/24/1998	Rubin et al.	
	AG	5,773,252	06/30/1998	Greene et al.	
	AH	5,773,586	06/30/1998	Gospodarowicz et al.	
\top	ΑI	5,814,605	09/29/1998	Pierce et al.	
	AJ	5,824,643	10/20/1998	Pierce et al.	
	AK	5,843,883	12/01/1998	Gospodarowicz et al.	
1	AL	5,863,767	01/26/1999	Gospodarowicz et al.	
	AM	6,077,692	06/20/2000	Ruben et al.	
1	AN	6,238,888 B1	05/29/2001	Gentz et al.	

			FOREIGN PAT	ENT DOCUMENTS		
		Foreign Patent Document	D. Adication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	™
XZ	AO	WO 90/08771	08/09/1990	Rubin et al.		$oxed{oxed}$
	AP	WO 92/14480	09/03/1992	Amgen Inc.		L
	AQ	WO 92/22304	12/23/1992	Amgen Inc.		
	AR	WO 93/21908	11/11/1993	Amgen Inc.		
	AS	EP 0 619 370 A1	10/12/1994	Amgen Inc.		
	ĀT	WO 94/22427	10/13/1994	Amgen Inc.	·	L
	AU	WO 94/23032	10/13/1994	Amgen Inc.		
<u> </u>	AV	WO 95/01434	01/12/1995	Chiron Inc.		\perp
₩	AW	WO 95/03831	02/09/1995	Prizm Pharmaceuticals, Inc.		<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Examiner Signature	Date Considered	3/1/06

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁸Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	stitute for form 1449A/P	το		Complete if Known	
0000				Application Number	Not Yet Assigned
iN	IFORMATIC	ON DIS	SCLOSURE	Filing Date	Herewith
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Reiner L. Gentz
	,,,,,	_ , .		Art Unit	N/A
	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned
Sheet	2	of	8	Attorney Docket Number	PF402C1D1

			FOREIGN PATI	ENT DOCUMENTS		
Examii Initials		Foreign Patent Document Country Code®-Number®-Kind Code® (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Xi	Z AX WO 95/24928 09/21/1995 Sumitomo Pharmaceuticals Co., Ltd.					
	AY	WO 95/24928 A3	09/21/1995	Sumitomo Pharmaceuticals Co., Ltd.		
	AZ	JP 7-345689	12/07/1995	Sumitomo Pharmaceuticals Co., Ltd.		
	BA	JP 8-103240	03/28/1996	Sumitomo Pharmaceuticals Co., Ltd.		
	BB	WO 96/11949	04/25/1996	Amgen Inc.		L
	BC	WO 96/11950	04/25/1996	Amgen Inc.		
\vdash	BD	WO 96/11951	04/25/1996	Amgen Inc.		
Н	BE	WO 96/11952	04/25/1996	Amgen Inc.		
	BF	JP 8-214378	07/24/1996	Sumitomo Pharmaceuticals Co., Ltd.		
H	BG	WO 96/22369	07/25/1996	Amgen Inc.		1_
	BH	WO 96/25422	08/22/1996	Human Genome Sciences, Inc.		1_
	BI	WO 97/20929	12/06/1997	Sumitomo Pharmaceuticals Co., Ltd.		
	BJ	WO 98/06844	02/19/1998	Human Genome Sciences, Inc.		$oldsymbol{ol}}}}}}}}}}}}}}}}}$
	BK	WO 98/16243	04/23/1998	Amgen, Inc.		
П	BL	WO 98/16642	04/23/1998	Amgen, Inc.		
	BM	GB 2 321 852 A	08/12/1998	Rohto Pharmaceutical Co. Ltd.		L
	BN	JP 10-330283	12/15/1998	Sumitomo Seiyaku Corp. Ltd.		
	ВО	JP 10-330284	12/15/1998	Sumitomo Seiyaku Corp. Ltd.		1_
	BP	JP 10-330285	12/15/1998	Sumitomo Seiyaku Corp. Ltd.		
	BQ	WO 99/32135	07/01/1999	Human Genome Sciences, Inc.		Ŀ
	BR	WO 99/41282	08/19/1999	Human Genome Sciences, Inc.		
	BS	WO 00/72872	12/07/2000	Human Genome Sciences, Inc.		ot

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Examiner Signature	Z	Date Considered	3/1/06

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁸Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)

Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ond to a collection of information unless it contains a valid OMB control number.

Subs	Substitute for form 1449A/PTO			Complete if Known		
000				Application Number	Not Yet Assigned	
١N	IFORMATION	ON DISC	CLOSURE	Filing Date	Herewith	
S	TATEMEN'	T BY AP	PLICANT	First Named Inventor	Reiner L. Gentz	
Ū				Art Unit	N/A	
	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	8	Attorney Docket Number	PF402C1D1	

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,			
Examiner Initials*	Cite No.'	Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	7°		
XZ	ВТ	WO 01/02433	01/11/2001	Human Genome Sciences, Inc.				
<u> </u>	BU	EP 0 619 115	10/12/1994	Amgen, Inc.		↓_		
V	BV	EP 0 518 697	12/16/1992	Amgen, Inc.	<u></u>	<u> </u>		

		OTHER - NON PATENT LITERATURE DOCUMENTS	_
xaminer nitials	No. term (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), which is serial, symposium, catalog, etc), date, page(s), etc), etc		Τ²
xZ	BW	BOWIE, J.U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247:1306-1310, American Association for the Advancement of Science (1990).	
	BX	CHEN et al. "Stabilization of recombinant human keratinocyte growth factor by osmolytes and salts", J. Pharm. Sciences 85(4):419-422 (1996).	
	BY	CHEN et al. "Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization", Pharmaceutical Research 11(11):1581-1587 (1994).	
	BZ	FINCH, P.W., et al., "Human KGF Is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth," <i>Science</i> 245:752-755, American Association for the Advancement of Science (1989).	
	CA	HARTUNG, H., et al., "Murine FGF-12 and FGF-13: expression in embryonic nervous sytem, connective tissue and heart," Mech. Dev. 64:31-39, Elsevier Science Ireland Ltd. (1997).	
	СВ	HARTUNG, H., et al., "Assignment ^a of Fgf12 to mouse chromosome bands 16B1→B3 in situ hybridization," Cytogenet. Cell Genet. 76:185-186, Karger A.G. (1997).	
\bigvee	CC	JIMENEZ, P., et al., "Effect of Topical Keratinocyte Growth Factor-2 on Wound Healing In A Glucocorticoid-Impaired Model," J. Cutan. Pathol. 24:105, Munksgaard (1997).	

Examiner Signature	Very 2:	Date Considered	. 3/1/06
	Y		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/PTO			Complete if Known		
				Application Number	Not Yet Assigned	
IN	NFORMATIC	N DI	SCLOSURE	Filing Date	Herewith	
S	TATEMENT	BY	APPLICANT	First Named Inventor	Reiner L. Gentz	
				Art Unit	N/A	
	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	4	of	8	Attorney Docket Number	PF402C1D1	

	I	OTHER - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the				
Examiner nitials	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2			
	CD	JIMENEZ, P.A., et al., "Effect of Keratinocyte Growth Factor-2 on Cell Proliferation				
χZ	1 1					
	CE					
		Wound Healing in Incisional Wounds," J. Surg. Res. 81:238-242, Academic Press, Inc. (1999).				
	CF	KELLEY, M.J., et al., "Emergence of the keratinocyte growth factor multigene	†			
		family during the great ape radiation," <i>Proc. Natl. Acad. Sci. USA</i> 89:9287-9291, National Academy of Sciences (1992).				
-	CF	MASON, I.J., et al., "FGF-7 (keratinocyte growth factor) expression during mouse	Τ			
1		development suggests roles in myogenesis, forebrain regionalisation and epithelial-	1			
		mesenchymal interactions," Mech. Dev. 45:15-30, Elsevier Science Ireland Ltd. (1994).				
_	CG	MIYAMOTO, M., et al., "Molecular Cloning of a Novel Cytokine cDNA Encoding				
		the Ninth Member of the Fibroblast Growth Factor Family, Which Has a Unique	Ì			
		Secretion Property," Mol. Cell. Biol. 13:4251-4259, American Society for				
- 1	ŀ	Microbiology (1993).				
-	CH	NGO, J.T., et al, "Computational Complexity, Protein Structure Prediction, and the	Ţ			
		Levinthal Paradox," in: The Protein Folding Problem and Tertiary Structure				
		Prediction, Merz, Jr., K. and Le Grand, S., eds., Birkhauser, Boston, Massachusetts,	-			
	ļ	pp. 491-495 (1994).	\perp			
\dashv	CI	ROBSON, B. and Garnier, J., "Modern ideas and notations relating to primary				
		structure," in: Introduction to Proteins and Protein Engineering," Robson, B. and	-			
		Garnier, J., eds., Elsevier Science, Amsterdam, The Netherlands, p.41 (1986).	\perp			
	CJ	RON, D., et al., "Expression of Biologically Active Recombinant Keratinocyte				
		Growth Factor," J. Biol. Chem. 268:2984-2988, American Society for Biochemistry	1			
		and Molecular Biology, Inc. (1993).				
1/	CK	WELLS, J.A., "Additivity of Mutational Effects in Proteins," Biochem. 29:8509-	1			
ץ		8517, American Chemical Society, (1990).				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Examiner Signature	Date Considered	3/1/06	
8	<u> </u>		

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible, ⁶Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/	PTO		Complete if Known		
	Situate for form 14-4070.			Application Number	Not Yet Assigned	
١N	IFORMATI	ON DIS	CLOSURE	Filing Date	Herewith	
S	STATEMENT BY APPLICANT			First Named Inventor	Reiner L. Gentz	
Ŭ	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Art Unit	N/A	
	(use as man	y sheets as n	ecessary)	Examiner Name	Not Yet Assigned	
heet	5	of	8	Attorney Docket Number	PF402C1D1	

ΧS	CL	SCOPES, R.K. "Protein Purification: Principles and Practice" (3 rd ed.) New York:	
χČ	1	Springer-Verlag (1994).	
	CM	YAMASAKI, M., et al., "Structure and Expression of the Rat mRNA Encoding a	
		Novel Member of the Fibroblast Growth Factor Family," J. Biol. Chem. 271:15918-	
		15921, American Society for Biochemistry and Molecular Biology, Inc. (1996).	
	CN	YAN, G., et al., "Sequence of Rat Keratinocyte Growth Factor (Heparin-Binding	
ì	1	Growth Factor Type 7)," In Vitro Cell. Dev. Biol. 27A:437-438, Tissue Culture	
1		Association (1991).	
_	CO	NCBI Entrez, GenBank Report with Revision History, Accession No. M79878,	
-		McCombie, W.R. et al., National Center for Biotechnology Information (June 1992).	
\dashv	CP	NCBI Entrez, GenBank Report with Revision History, Accession No. T52063,	
1	•	Hillier, L. et al., National Center for Biotechnology Information (February 1995).	
\dashv	CQ	NCBI Entrez, GenBank Report with Revision History, Accession No. D46201,	
ı	100	Sasaki, T. et al., National Center for Biotechnology Information (August 1995).	
\dashv	CR	NCBI Entrez, GenBank Report with Revision History, Accession No. D46420,	
	I CAR	Sasaki, T. et al., National Center for Biotechnology Information (August 1995).	
+	CS	NCBI Entrez, GenBank Report with Revision History, Accession No. D54216,	
1	103	Fujiwara, T. et al., National Center for Biotechnology Information (September	
1		1995).	
+	СТ	NCBI Entrez, GenBank Report with Revision History, Accession No. D68729,	Γ
- 1	-	Kohara, Y. et al., National Center for Biotechnology Information (December 1995).	L
+	CU	NCBI Entrez, GenBank Report with Revision History, Accession No. D69248,	Γ
		Kohara, Y. et al., National Center for Biotechnology Information (December 1995).	
\dashv	CV	NCBI Entrez, GenBank Report with Revision History, Accession No. D65627,	Γ
	10.	Kohara, Y. et al., National Center for Biotechnology Information (December 1995).	
_	CW	NCBI Entrez, GenBank Report with Revision History, Accession No. D66221,	Γ
	"	Kohara, Y. et al., National Center for Biotechnology Information (December 1995).	
-	CX	NCBI Entrez, GenBank Report with Revision History, Accession No. C02000,	
	1	Okubo, K., National Center for Biotechnology Information (July 1996).	L
	CY	NCBI Entrez, GenBank Report with Revision History, Accession No. W29377,	
	-	Marra, M. et al., National Center for Biotechnology Information (September 1996).	
-1,	CZ	NCBI Entrez, GenBank Report with Revision History, Accession No. W32720,	
\bigvee		Hillier, L. et al., National Center for Biotechnology Information (October 1996).	1
			T

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Examiner Signature	Date Considered	3/1/06	_

^{&#}x27;Applicant's unique citation designation number (optional). *See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the application number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ond to a collection of information unless it contains a valid OMB control number.

Subs	titute for form 1449A/F	PTO			Complete if Known
0000				Application Number	Not Yet Assigned
IN	IFORMATIO	ON DISC	LOSURE	Filing Date	Herewith
S	STATEMENT BY APPLICANT			First Named Inventor	Reiner L. Gentz
Ŭ				Art Unit	N/A
	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned
Sheet	6	of	8	Attorney Docket Number	PF402C1D1

V	5	DA	NCBI Entrez, GenBank Report with Revision History, Accession No. W60824,
X	ć		Hillier, L. et al., National Center for Biotechnology Information (October 1996).
ľ		DB	NCBI Entrez, GenBank Report with Revision History, Accession No. T70682, Shen,
ı		İ	B. et al., National Center for Biotechnology Information (October 1996).
		DC	NCBI Entrez, GenBank Report with Revision History, Accession No. AA094753,
1			Liew, C.C., National Center for Biotechnology Information (October 1996).
		DD	NCBI Entrez, GenBank Report with Revision History, Accession No. AA133331,
ľ			Hillier, L. et al., National Center for Biotechnology Information (November 1996).
		DE	NCBI Entrez, GenBank Report with Revision History, Accession No. AA190058,
		l	Marra, M. et al., National Center for Biotechnology Information (January 1997).
- 1		DF	NCBI Entrez, GenBank Report with Revision History, Accession No. AA018953,
		-	Hillier, L. et al., National Center for Biotechnology Information (January 1997).
		DG	NCBI Entrez, GenBank Report with Revision History, Accession No. AA240978,
- 1		-	Marra, M. et al., National Center for Biotechnology Information (March 1997).
		DH	NCBI Entrez, GenBank Report with Revision History, Accession No. AA289560,
	•		Marra, M. et al., National Center for Biotechnology Information (April 1997).
		DI	NCBI Entrez, GenBank Report with Revision History, Accession No. AA296993,
			Adams, M.D. et al., National Center for Biotechnology Information (April 1997).
		DJ	NCBI Entrez, GenBank Report with Revision History, Accession No. AA298937,
			Adams, M.D. et al., National Center for Biotechnology Information (April 1997).
		DK	NCBI Entrez, GenBank Report with Revision History, Accession No. AA312184,
			Adams, M.D. et al., National Center for Biotechnology Information (April 1997).
-		DL	NCBI Entrez, GenBank Report with Revision History, Accession No. AA312483,
1			Adams, M.D. et al., National Center for Biotechnology Information (April 1997).
		DM	NCBI Entrez, GenBank Report with Revision History, Accession No. AA356781,
			Adams, M.D. et al., National Center for Biotechnology Information (April 1997).
		DN	NCBI Entrez, GenBank Report with Revision History, Accession No. AA412789,
			Marra, M. et al., National Center for Biotechnology Information (May 1997).
\neg	7	DO	NCBI Entrez, GenBank Report, Accession No. U67918, Jimenez, P.A. et al.,
V	V	~~	National Center for Biotechnology Information (July 1997).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Examiner Signature	Date Considered	3/1/06
The same of the sa		

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)

Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/PTO			Complete if Known		
500			•	Application Number	Not Yet Assigned	
IN	IFORMATIO	N DI	SCLOSURE	Filing Date	Herewith	
S	STATEMENT BY APPLICANT			First Named Inventor	Reiner L. Gentz	
				Art Unit	N/A	
	(use as many st	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	7	of	8	Attorney Docket Number	PF402C1D1	

Y7	DP	NCBI Entrez, GenBank Report with Revision History, Accession No. AA472256, Marra, M. et al., National Center for Biotechnology Information (June 1997).
	DQ	NCBI Entrez, GenBank Report with Revision History, Accession No. C38464, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DR	NCBI Entrez, GenBank Report with Revision History, Accession No. C56505, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DS	NCBI Entrez, GenBank Report with Revision History, Accession No. C57074, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DT	NCBI Entrez, GenBank Report with Revision History, Accession No. C58558, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DU	NCBI Entrez, GenBank Report with Revision History, Accession No. C58846, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DV	NCBI Entrez, GenBank Report with Revision History, Accession No. C59317, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DW	NCBI Entrez, GenBank Report with Revision History, Accession No. C59311, Kohara, Y. et al., National Center for Biotechnology Information (September 1997).
	DX	NCBI Entrez, GenBank Report with Revision History, Accession No. AA605609, Clark, M. et al., National Center for Biotechnology Information (September 1997).
	DY	NCBI Entrez, GenBank Report with Revision History, Accession No. AA621871, NCI-CGAP, National Center for Biotechnology Information (October 1997).
	DZ	NCBI Entrez, GenBank Report with Revision History, Accession No. AA621888, NCI-CGAP, National Center for Biotechnology Information (October 1997).
	EA	NCBI Entrez, GenBank Report with Revision History, Accession No. AA675470, Marra, M. et al., National Center for Biotechnology Information (November 1997).
	ЕВ	NCBI Entrez, GenBank Report with Revision History, Accession No. AA675519, Marra, M. et al., National Center for Biotechnology Information (November 1997).
	EC	NCBI Entrez, GenBank Report with Revision History, Accession No. AA838994, Marra, M. et al., National Center for Biotechnology Information (February 1998).
	ED	NCBI Entrez, GenBank Report with Revision History, Accession No. H35048, Lee, N.H. et al., National Center for Biotechnology Information (April 1998).
	EE	NCBI Entrez, GenBank Report with Revision History, Accession No. AA906051, NCI-CGAP, National Center for Biotechnology Information (May 1998).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Examiner S S S S S S S S S S S S S S S S S S S	Date Considered	3	/1	106	
Signature	Considered				

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number.

Subs	stitute for form 1449A/F	PTO		Complete if Known		
305.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Application Number	Not Yet Assigned	
IN	IFORMATION	ON DIS	CLOSURE	Filing Date	Herewith	
S	STATEMENT BY APPLICANT			First Named Inventor	Reiner L. Gentz	
Ŭ	.,			Art Unit	N/A	
•	use as man	y sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	8	of	8	Attorney Docket Number	PF402C1D1	

ΧZ	EF	NCBI Entrez, GenBank Report with Revision History, Accession No. C78836, Ko, M.S.H. et al., National Center for Biotechnology Information (June 1998).
	EG	Dialog File 351, Accession No. 12329483, Derwent WPI English language abstract for JP 10-330283.
	ЕН	Dialog File 351, Accession No. 12294894, Derwent WPI English language abstract for JP 10-330284.
	EI	Dialog File 351, Accession No. 12303256, Derwent WPI English language abstract for JP 10-330285.
	EJ	English language translation of WO 97/20929 (Document BH).
	EK	English language translation of JP 7-345689 (Document AY).
	EL	English language translation of JP 8-103240 (Document AZ).
	EM	English language translation of JP 8-214378 (Document BE).
	EN	English language translation of JP 10-330283 (Document BM).
	EO	English language translation of JP 10-330284 (Document BN).
	EP	English language translation of JP 10-330285(Document BO).

Examiner Signature	Date Considered	3/	1/06
		•	•

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional), ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.